Global, multicenter, randomized, phase ii trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Liver Neoplasms
  • Pancreatic Neoplasms

abstract

  • This randomized, phase II study achieved its primary end point, demonstrating an improved 6-month SR with addition of AGS-1C4D4 to gemcitabine among patients with previously untreated, metastatic pancreatic adenocarcinoma. ClinicalTrials.gov identifier: NCT00902291.

publication date

  • July 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3716216

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdt066

PubMed ID

  • 23448807

Additional Document Info

start page

  • 1792

end page

  • 801

volume

  • 24

number

  • 7